Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Meet Sutton's Drug Store owner Don Pinney
Opened in 1923 by Lynwood and Lucy Sutton, Sutton's Drug Store was sold to Elliott Brummitt in 1965 with the understanding that the store wouldn’t...
Fri Feb 27, 2026

Carolina Covenant Documentary Wins Emmy
Chase Martin, assistant director of video for university development, and Jeyhoun Allebaugh, assistant director of photo and video for university development, accepted the best educational...
Wed Feb 25, 2026

When Every Second Counts: This UNC Device is Saving Lives
A breakthrough from UNC is helping frontline teams fight America’s drug crisis. Chemist Mike Ramsey’s research led to the MX908, a handheld mass spectrometer, that...
Sun Feb 22, 2026

Forbes Names Carolina to “Best Large Employer” List
The University of North Carolina is the top-ranked public institution in North Carolina on the Forbes 2026 Best Large Employer List released Tuesday. UNC is...
Sat Feb 21, 2026